Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data
13th October 2021 Uncategorised 0Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI More: Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data Source: News
read more